Clinical studies at the Rostock/Greifswald site

ARCA (Autosomal-Recessive Cerebellar Ataxias)

In this DZNE network research project (Autosomal Recessive Cerebellar Ataxia Registry, ARCA registry), modern methods are being used to search for new ataxia genes and biomarkers in autosomal recessive ataxias and early onset ataxias with onset before the age of 40.

DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)

One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.

DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)

In order for us to assess study outcomes of patients with neurological frontotemporal dementia (FTD), comparative studies with relatives of patients with FTD as well as interested individuals without a diagnosis of neurodegenerative disease are needed.

DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)

Comparative studies with relatives of patients with PSP and interested individuals without a diagnosis of neurodegenerative disease are needed to assess study outcomes of patients with progressive supranuclear palsy (PSP).

DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)

The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.

DESCRIBE-Cognition (DZNE - Klinische Registerstudie zur kognitiven Leistungsfähigkeit bei Alzheimer-Erkrankungen)

Alzheimer's disease is the most common cause of dementia. Although research has made progress in recent years, there are still many unanswered questions, particularly regarding the progression of the disease and early changes.

DESCRIBE-FTD/ALS (DZNE Clinical Registry Study on Frontotemporal Dementia (FTD) & on Amyotrophic lateral sclerosis (ALS))

The aims of this studies are to describe the course of FTD and ALS in detail, in their various characteristic clinical forms, to improve our understanding of the underlying pathology and to identify effective parameters for diagnosis and forecasting of the diseases' progression. This work is expected to illuminate the causes of the diseases, and to provide a basis for better therapies that can be applied at earlier stages of the diseases.

DESCRIBE-PD (DZNE Clinical Registry Study of Neurodegenerative Diseases on Patients with sporadic and familial Parkinson's syndromes (PD) and Idiopathic REM Sleep Behavior Disorder)

Longitudinal clinical observation is intended to identify subgroups of the disease with different clinical courses and determine their causes. In addition, the study aims to identify specific biomarkers to enable the earliest possible diagnosis and prognosis, as well as to differentiate the condition from other neurodegenerative diseases. Individuals with idiopathic REM sleep behavior disorder will also be included, as this may be a precursor to Parkinson’s disease.

DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))

The aim of the DESCRIBE-PSP study is to document the early and atypical course of PSP in order to enable improved diagnostic criteria and therapy studies in the early course of the disease.

DESCRIBE-Treatment (DZNE - Clinical Registry Study on the documentation of innovative therapies)

The DZNE therefore aims to examine participants over time through regular assessments as part of this study. The study is open to people who are being treated with newly approved therapies or new therapies that become available in the future.

DZNE-CAA (DZNE Cerebral Amyloid Angiopathy Study)

Cerebral amyloid angiopathy (CAA) is a disease of the vessels in the brain in which proteins, known as amyloid, are deposited in the walls of the vessels. There are initial indications of possible mechanisms and biomarkers that influence the course of the disease, but there are still many unanswered questions.

Education for relatives "Living with dementia"

Training series for relatives: Positive effects in care by providing background knowledge and showing possibilities in the daily handling of people with dementia as well as suitable relief and care strategies so that people with dementia can be cared for longer in the home.

ENABLE (Patient- and care-related benefits of amyloid PET imaging)

The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.

EPND Glossary Feedback Survey

>>> This survey only addresses EPND members. <<< The European Platform for Neurodegenerative Diseases (EPND) Glossary was established to provide the basis for a consistent, high-quality use of terminology for neurodegenerative diseases.

HSP-Net (Networking Project on Hereditary Spastic Paraplegia)

Spastic spinal paralysis (HSP) is a rare, often hereditary, slowly progressive disease characterized by a spastic gait disorder. The HSP project involves the establishment and conduct of a multicenter study of the natural longitudinal course of hereditary spastic spinal paralysis.

PROFA (Patient-reported, health economic and psychosocial outcomes in Friedreich Ataxia)

Investigation of the impact of Friedreich's ataxia on patient-related, health economic, and psychosocial outcomes using self-reported data collection via a patient-centered e-health app.

PROMINENT (Improving the management of Alzheimer’s disease)

PROMINENT is a collaborative pan-European public-private partnership funded through the Innovative Health Initiative (IHI). It will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities to assist clinicians with individualised decision support in the evaluation of patients with suspected cognitive impairment.

Refer-MCI (Enriching referrals of patients to memory clinics for mild cognitive impairment (MCI))

The use of digital technologies is intended to optimize the referral practice of patients with MCI to memory clinics. The study will examine how digital self-testing tools can improve referral practice, what role biomarkers play in identifying MCI due to Alzheimer's disease, and how these digital tools compare to established tests.

SPORTAX-NHS (Observational Study on Adult Onset Sporadic Ataxias)

The SPORTAX study aims to precisely characterize the two forms of the disease and to compare the courses of the disease. In addition, factors are to be identified that allow a more precise assignment of the disease at an early stage and that can influence the development of the disease.